The combination of AGS-003 and sunitinib yielded supportive immunologic responses and extended survival in intermediate- or poor-risk patients with metastatic renal cell carcinoma, according to data from a phase 2 trial.AGS-003 (Argos Therapeutics) is a novel autologous immunotherapeutic agent created from the patient’s own dendritic cells co-electroporated with amplified tumor RNA and synthetic CD40L RNA, according to study background.
No comments:
Post a Comment